FDA Drug Recalls
2,357 recalls · Class II, newest first
Jun 20, 2025
Class II · Moderate risk
Product Mix Up: This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg.
Jun 20, 2025
Class II · Moderate risk
Subpotent Drug: Assay below the approved specification
Jun 20, 2025
Class II · Moderate risk
Subpotent Drug: Assay below the approved specification
Jun 20, 2025
Class II · Moderate risk
Subpotent Drug: Assay below the approved specification
Jun 20, 2025
Class II · Moderate risk
Subpotent Drug: Assay below the approved specification
Jun 20, 2025
Class II · Moderate risk
Subpotent Drug: Assay below the approved specification
Jun 20, 2025
Class II · Moderate risk
Subpotent Drug: Assay below the approved specification
Jun 20, 2025
Class II · Moderate risk
Subpotent Drug: Assay below the approved specification
Jun 19, 2025
Class II · Moderate risk
Defective container; blister packaging inadequately sealed.
Jun 19, 2025
Class II · Moderate risk
Defective container; blister packaging inadequately sealed.
Jun 16, 2025
Class II · Moderate risk
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 9 month long term stability station (25¿C, 60%RH).
Jun 16, 2025
Class II · Moderate risk
Lack of assurance of sterility: pinholes, within the finger boxes used during Form Fill Seal process resulting in leaks.
Jun 10, 2025
Class II · Moderate risk
Jun 2, 2025
Class II · Moderate risk
Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.
Jun 2, 2025
Class II · Moderate risk
Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.
Jun 2, 2025
Class II · Moderate risk
Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.
Jun 2, 2025
Class II · Moderate risk
Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.
Jun 2, 2025
Class II · Moderate risk
Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.
Jun 2, 2025
Class II · Moderate risk
Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.
May 30, 2025
Class II · Moderate risk
Marketed Without an Approved NDA/ANDA
May 29, 2025
Class II · Moderate risk
Failed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis.
May 28, 2025
Class II · Moderate risk
Lack of Assurance of Sterility
May 28, 2025
Class II · Moderate risk
Lack of Assurance of Sterility
May 28, 2025
Class II · Moderate risk
Lack of Assurance of Sterility
May 28, 2025
Class II · Moderate risk
Discoloration; discolored solution from cracked vials